Details
Stereochemistry | ACHIRAL |
Molecular Formula | C23H13Cl2N3O2 |
Molecular Weight | 434.274 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
ClC1=CC=C(Cl)C(=C1)C2=CC=C(O2)\C=C(/C#N)C(=O)NC3=C4C=CC=NC4=CC=C3
InChI
InChIKey=SVENPFFEMUOOGK-SDNWHVSQSA-N
InChI=1S/C23H13Cl2N3O2/c24-15-6-8-19(25)18(12-15)22-9-7-16(30-22)11-14(13-26)23(29)28-21-5-1-4-20-17(21)3-2-10-27-20/h1-12H,(H,28,29)/b14-11+
Molecular Formula | C23H13Cl2N3O2 |
Molecular Weight | 434.274 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/17588900 |
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17588900 |
The histone deacetylases (HDACs), Sirtuin 1 (Sirt1) and Sirt2, play crucial roles in many biological processes, including cell proliferation, differentiation, and apoptosis. AGK2 is a cell-permeable, selective inhibitor of sirtuin 2 (SIRT2), which as was shown, prevented cellular α-tubulin deacetylation in HeLa cells in a dose-dependent manner and with little cytotoxic effect. AGK2 can be a useful tool for studying the roles of SIRT2 in neurodegeneration and aging, as well as cell cycle progression and tumorigenesis.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Q8IXJ6|||U5TP13 Gene ID: 22933.0 Gene Symbol: SIRT2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/17588900 |
3.5 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17588900
It was examined insoluble, polymerized microtubules and soluble alpha-tubulin after treatment of HeLa cells with either AGK2 or AGK3, a less potent structural analog of AGK2, for 3 hours. A dose dependent increase in acetylated tubulin was observed in both fractions of AGK2 treated cells relative to untreated or AGK3-treated cells. Thus, AGK2 could enter cells and act on endogenous SIRT2 in its native environment. AGK2 (5, 10, 20, 30, 40, 50 Um) treatment results in a dose-dependent increase in acetylation of soluble tubulin monomers (S) and polymerized microtubules (P) in fractionated HeLa cell extracts. The effect of the less potent SIRT2 inhibitor AGK3 was shown for comparison.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 09:00:27 GMT 2023
by
admin
on
Sat Dec 16 09:00:27 GMT 2023
|
Record UNII |
DDF0L8606A
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
2130404
Created by
admin on Sat Dec 16 09:00:27 GMT 2023 , Edited by admin on Sat Dec 16 09:00:27 GMT 2023
|
PRIMARY | |||
|
DTXSID80184559
Created by
admin on Sat Dec 16 09:00:27 GMT 2023 , Edited by admin on Sat Dec 16 09:00:27 GMT 2023
|
PRIMARY | |||
|
DDF0L8606A
Created by
admin on Sat Dec 16 09:00:27 GMT 2023 , Edited by admin on Sat Dec 16 09:00:27 GMT 2023
|
PRIMARY | |||
|
304896-28-4
Created by
admin on Sat Dec 16 09:00:27 GMT 2023 , Edited by admin on Sat Dec 16 09:00:27 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |